Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results in clinical study

The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of XSTEM. Xintela has previously communicated positive interim results up to 18 months after treatment of knee osteoarthritis patients with three dose levels of XSTEM. The highest dose level, which showed the best results after 18 months, has now shown sustained positive treatment effects two years after XSTEM treatment. 

XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela.